{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:59:04Z","timestamp":1786593544253,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T00:00:00Z","timestamp":1493942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Monoclonal antibodies (mAb) targeting PD-1\/PD-L1 have revolutionized melanoma treatment, yet data regarding effectiveness and tolerability across age groups is limited. We sought to determine the impact of age on overall survival (OS), progression-free survival (PFS), and rates of immune-mediated toxicities in patients treated with anti\u2013PD-1\/anti-PD-L1 mAb at two academic medical centers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively collected data on all patients with metastatic melanoma treated with anti-PD-1\/PD-L1 mAb between May 2009 and April 2015. We used Kaplan-Meier and Cox regression analyses to assess OS and PFS and identify factors associated with these outcomes. We also compared rates of autoimmune toxicity across age groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 254 patients, 57 (22.4%) were &amp;lt;50 years old, 85 (33.5%) were age 50\u201364, 65 (25.6%) were age 65\u201374, and 47 (18.5%) were \u226575 years. Across age groups, no differences existed in median OS (age &amp;lt;50: 22.9 months, age 50\u201364: 25.3 months, age 65\u201374: 22.0 months, age \u226575: 24.3 months) or PFS (age &amp;lt;50: 4.1 months, age 50\u201364: 6.5 months, age 65\u201374: 5.4 months, age \u226575: 7.9 months). The presence of liver metastases and elevated pre-treatment lactate dehydrogenase (LDH) were associated with reduced OS. Presence of liver metastasis, pretreatment LDH, BRAF mutation, and type of melanoma correlated with PFS. Overall, 110 patients (43.3%) experienced immune-mediated toxicities; 25 (9.8%) had colitis and 26 (10.2%) had endocrine toxicity. Rates of colitis, hepatitis, and pneumonitis did not differ across age groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We demonstrated that patients could safely tolerate anti-PD1\/PDL-1 mAb therapy and achieve similar outcomes regardless of their age.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0450","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T01:00:28Z","timestamp":1494032428000},"page":"963-971","source":"Crossref","is-referenced-by-count":173,"title":["Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma"],"prefix":"10.1093","volume":"22","author":[{"given":"Allison S.","family":"Betof","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Nipp","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Computational Biology Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romany A. N.","family":"Johnpulle","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Rubin","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel M.","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,5]]},"reference":[{"key":"2021122508145695500_onco12146-bib-0001","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0002","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"2021122508145695500_onco12146-bib-0003","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0004","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0006","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0007","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0008","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0010","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0011","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0012","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0013","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"2021122508145695500_onco12146-bib-0014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"2021122508145695500_onco12146-bib-0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0016","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0017","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0018","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"2021122508145695500_onco12146-bib-0019","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2021122508145695500_onco12146-bib-0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0021","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122508145695500_onco12146-bib-0022","doi-asserted-by":"crossref","first-page":"LBA6008","DOI":"10.1200\/jco.2015.33.18_suppl.lba6008","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort","volume":"33","author":"Seiwert","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0023","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12029-016-9806-8","article-title":"Advances of molecular targeted therapy in gastric cancer","volume":"47","author":"Cetin","year":"2016","journal-title":"J Gastrointest Cancer"},{"key":"2021122508145695500_onco12146-bib-0024","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","article-title":"Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience","volume":"25","author":"Muss","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0025","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.293.9.1073","article-title":"Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer","volume":"293","author":"Muss","year":"2005","journal-title":"JAMA"},{"key":"2021122508145695500_onco12146-bib-0026","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1200\/JCO.2005.04.5005","article-title":"Duration of adjuvant chemotherapy for colon cancer and survival among the elderly","volume":"24","author":"Neugut","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0027","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1200\/JCO.2003.02.046","article-title":"Undertreatment strongly decreases prognosis of breast cancer in elderly women","volume":"21","author":"Bouchardy","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0028","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122508145695500_onco12146-bib-0029","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1200\/JCO.2002.08.056","article-title":"How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials","volume":"20","author":"Sateren","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0030","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: Known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0031","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jgo.2016.02.005","article-title":"Pragmatic study designs for older adults with cancer: Report from the U13 conference","volume":"7","author":"Nipp","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"2021122508145695500_onco12146-bib-0032","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","article-title":"Review of survival analyses published in cancer journals","volume":"72","author":"Altman","year":"1995","journal-title":"Br J Cancer"},{"key":"2021122508145695500_onco12146-bib-0033","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40266-015-0304-7","article-title":"Novel therapies for metastatic melanoma: An update on their use in older patients","volume":"32","author":"Rogiers","year":"2015","journal-title":"Drugs Aging"},{"key":"2021122508145695500_onco12146-bib-0034","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.critrevonc.2009.06.002","article-title":"The role of immunity in elderly cancer","volume":"74","author":"Malaguarnera","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122508145695500_onco12146-bib-0035","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1172\/JCI64096","article-title":"Causes, consequences, and reversal of immune system aging","volume":"123","author":"Montecino-Rodriguez","year":"2013","journal-title":"J Clin Invest"},{"key":"2021122508145695500_onco12146-bib-0036","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.1991.9.8.1500","article-title":"Socioeconomic status and cancer survival","volume":"9","author":"Cella","year":"1991","journal-title":"J Clin Oncol"},{"key":"2021122508145695500_onco12146-bib-0037","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122508145695500_onco12146-bib-0038","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/1055-9965.EPI-11-0729","article-title":"Cancer survivors: A booming population","volume":"20","author":"Parry","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122508145695500_onco12146-bib-0039","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of cancer incidence in the United States: Burdens upon an aging, changing nation","volume":"27","author":"Smith","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/8\/963\/41914415\/oncolo_22_8_963.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/8\/963\/41914415\/oncolo_22_8_963.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:15:56Z","timestamp":1640420156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/8\/963\/6444423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,5,5]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0450","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8,1]]},"published":{"date-parts":[[2017,5,5]]}}}